R&D | October 28, 2025
Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The event will be attended by 35,000+ industry professionals
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Subscribe To Our Newsletter & Stay Updated
